Frost et al. identified KRAS/TP53 co-mutation as a biomarker for long-term response to pembrolizumab monotherapy in lung adenocarcinoma with high ( ≥ 50%) PD-L1 expression [12, 13]. Here, TP53 is linked to lung adenocarcinoma.